Micro-X Reports 16% Revenue Increase and $9.9 Million Loss in FY26
Micro-X Limited lifted revenues by 16% to $15.1 million for FY26 but posted a $9.9 million net loss, narrowing from the prior year. The company advanced key medical imaging milestones and initiated a strategic reset to sharpen commercial focus and reduce costs.
- Revenue increased 16% to $15.1 million
- Net loss narrowed 29% to $9.9 million
- First human imaging with Head CT achieved
- $8 million convertible notes secured post-year-end
- Strategic reset targets $3 million annual cost savings
Revenue Growth Masks Persistent Losses
Micro-X Limited (ASX:MX1) posted a 16% rise in revenues to $15.1 million for the year ended 30 June 2026, buoyed by increased sales of its Rover Plus mobile digital X-ray systems and contracted development income. However, the company’s loss after tax narrowed only modestly, falling 29% to $9.9 million. Despite the revenue boost, Micro-X remains unprofitable, reflecting the challenges of scaling commercial sales while investing heavily in research and development.
Advancing Carbon Nanotube Imaging Technology
The company marked a significant technical milestone with the first human imaging using its proprietary carbon nanotube (CNT) Head CT scanner at the Royal Melbourne Hospital, progressing a multi-centre pilot study aimed at stroke diagnosis. This development underscores Micro-X’s ambition to disrupt conventional CT imaging by delivering portable, lightweight systems that can bring advanced diagnostics closer to patients, including in ambulances and regional hospitals.
Further technical progress includes completion of the critical design review for the Full Body CT system under a US government ARPA-H program, moving towards prototype manufacturing. These initiatives are funded through substantial government contracts and partnerships, including $5.6 million from ARPA-H and $3.3 million from the U.S. Department of Homeland Security (DHS) for security screening technologies.
Strategic Reset and Leadership Change
In August 2026, Micro-X appointed Brian Gonzales as CEO, tasking him with translating technical achievements into commercial success amid a strategic reset. The company aims to sharpen its commercial priorities, reduce its cost base by over $3 million annually (approximately 15% of FY26 operating costs), and restructure its sales function following a consultancy review. Gonzales’s mandate includes improving product sales, margins, and reducing the company’s reliance on shareholder capital.
Micro-X raised $6.18 million via a placement during FY26 and secured $8 million in convertible note commitments post-year-end, with settlement expected by October 2026. The notes bear 12% interest, convert at $0.08 per share, and are secured by company assets. Conversion could dilute existing shareholders by issuing up to 100 million shares.
Commercial and Funding Risks Remain
The company’s path to profitability hinges on converting its development programs into sustainable product sales. While Rover Plus sales grew to $5.4 million, including a record $3.3 million sale to Malaysia’s Ministry of Health and a supply agreement with a major US healthcare provider, the sales pipeline requires strengthening to support ongoing operations.
Funding for development programs is milestone-dependent, notably the ARPA-H Full Body CT contract which faces a down-selection decision by November 2026. Failure to meet milestones or secure additional commercial partnerships, especially in security screening, could jeopardise funding and delay product launches. The company also faces risks related to manufacturing scale-up, regulatory approvals, and competition from better-resourced incumbents.
Balance Sheet and Going Concern Considerations
Micro-X ended FY26 with $3.1 million in cash and net assets of $5 million, a decline from the prior year. Operating cash outflows were $8.9 million. The board acknowledges material uncertainty regarding the company’s ability to continue as a going concern but considers the convertible note funding, contracted development receipts of $8.1 million, expected R&D tax incentive refund, and cost savings sufficient to fund operations through FY27, assuming milestone achievements and note settlement.
Investors should note that the convertible notes’ security over company assets and mandatory conversion clauses introduce dilution and financial risk. The company’s future depends heavily on execution of its strategic reset, commercial traction with Rover Plus and emerging CT products, and successful navigation of regulatory and funding milestones.
Bottom Line?
Micro-X’s FY26 results highlight advancing technology and strategic recalibration but underline the urgency of commercial execution and capital management to reach sustainable profitability.
Questions in the middle?
- Will Micro-X’s Head CT clinical validation and regulatory submissions meet FY27 targets?
- Can the restructured Rover sales function convert pipeline opportunities into material revenue growth?
- What impact will the convertible note dilution and funding risks have on shareholder value?
